V114
V114 is a biological therapy with 21 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 21 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
1
Mid Stage
19
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
100.0%
21 of 21 finished
0.0%
0 ended early
0
trials recruiting
21
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
V114 and Acute Otitis Media (V114-032/PNEU-ERA)
Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)
Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028)
Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036)
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)
Clinical Trials (21)
V114 and Acute Otitis Media (V114-032/PNEU-ERA)
Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)
Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028)
Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036)
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)
Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)
Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033)
Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)
A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)
Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED)
Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)
A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)
Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024)
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)
Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE)
Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 21